4Ruan G, Feng SS. Preparation and characterization of poly(lactic acid )-poly ( ethylene glycol )-poly ( lactic acid )(PLA-PEG-PLA) microspheres for controlled release of pachtaxel[J]. Biomatrials, 2003, 24(27):5037-5044.
5Strieth S, Eichhom ME, Sauer B, et al. Neovascular targeting chemotherapy: encapsulation of paclitaxel in cationic liposomes impairs functional tumor microvasculature[J]. Int J Cancer, 2004, 110(1):117- 124.
6Kang BK, Chon SK, Kim SH, et al. Controlled release of paclitaxel from microemulsion containing PLGA and evaluation of antitumor activity in vitro and in vivo [ J ]. Int J Pharm, 2004, 286(1/2) : 147 - 156.
7Le Garrec D, Coil S, Luo L, et al. Poly(N-vinylpyrrolidone)-block-poly-(D, L-lactide) as a new polymeric solubilizer for hydrophobic anticancer drugs: in vitro and in vivo evaluation[J]. J Control Release, 2004, 99(1) :83 - 101.
8Feng SS, Mu L, Win KY, et al. Nanoparticles of biodegradable polymers for clinical administration of paclitaxel[J]. Curr Med Chem , 2004, 11(4):413-424.
9Plaisant N, Quenet F, Fabbro M, et al. Secondary debulking surgery and intraperitoneal chemotherapy in advancedor recurrent epithelial ovarian cancer [J]. Gynecol Obstet Fertil, 2004, 32(5) :391 - 397.
10Rothenberg ML, Lin PY, Braly PS, et al. Combined intraperitoneal and intravenous chemotherapy for women with optimally debulked ovarian cancer: results from an intergroup phase Ⅱ trial [ J ]. J Clin Oncol, 2003, 21 (7) :1313- 1319.
